



The Medicines Patent Pool Foundation

Governance Board Meeting Chairman's Summary

22 July 2014



The Governance Board of the Medicines Patent Pool (MPP) thank the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and Gilead on the proposed amendments to the existing Licence Agreement between MPP and Gilead Sciences in order to incorporate tenofovir alafenamide (TAF).

The Board has reviewed the EAG report and the proposed amendments and agrees with the EAG's assessment that they are consistent with the MPP's mandate as defined in its Statutes and Memorandum of Understanding with UNITAID, and represent a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with Gilead to formalise this collaboration. The Board further recommends that the MPP continues to seek the inclusion of all people living with HIV in low- and middle-income countries in this and other future collaborations.